A Phase 1 interventional study of AHB-171 Injection and Placebo in Chronic Hepatitis B Infection, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Ausper Biopharma Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. — 8 open to participants now, 11 under way, 1 of them phase 3. Hepatitis B, Chronic · Ausper Biopharma Co., Ltd..
Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 9th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →8 of the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18+
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65
By country, each count listing its studies:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 1
First in 2023; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 110 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 110 across the 12 interventional studies, 200 across the 1 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ausper Biopharma Co., Ltd. is the lead sponsor of 14 studies on the registry; 9 are open to participants now.
6 of the studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07137910Ausper Biopharma Co., Ltd.A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | 2026-12-12 |
| NCT07884864Ausper Biopharma Co., Ltd.A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants | 2027-04-30 |
| NCT07635186Ausper Biopharma Co., Ltd.A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | 2027-06-20 |
| NCT07069569Ausper Biopharma Co., Ltd.A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AHB-171 Injection Drug: Placebo Drug: Nucleos(t)ide Analogue (NA) Background treatment
Drug: AHB-171 Injection · Drug: Placebo · Drug: Nucleos(t)ide Analogue (NA)
Drug: AHB-171Injection Drug: Placebo
Drug: AHB-171 Injection · Drug: Placebo
AHB-171 Injection is adminstrated via subcutaneous injection
Placebo is admistrated via subcutaneous injection
Oral administration
Part A & Part B Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Change from baseline in laboratory tests
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Change from baseline in physical examinations
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Change from baseline in vital signs
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Change from baseline in electrocardiograms (ECGs)
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Part A:Plasma Cmax of AHB-171
Time frame: Up to Day 8
Part A:Plasma Tmax of AHB-171
Time frame: Up to Day 8
Part A Plasma AUC of AHB-171
Time frame: Up to Day 8
Part A Plasma t1/2 of AHB-171
Time frame: Up to Day 8
Proportion of participants with clinically significant abnormalities in laboratory tests
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Proportion of participants with clinically significant abnormalities in electrocardiograms (ECGs)
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Proportion of participants with physical examinations
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Proportion of participants with other vital signs
Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
Part A & Part B:Fraction excreted in urine in percentage for AHB-171
Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B
Part A & Part B:Amount excreted in urine for AHB-171
Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B
Part A & Part B:Renal clearance for AHB-171
Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B
Part A & Part B: Immunogenicity: The number of participants develop anti-drug antibodies (ADA) against AHB-171 and the ADA antibody titer
Time frame: Up to 16 weeks in Part A; Up to 48 weeks in Part B
Part B:Plasma Cmax of AHB-171
Time frame: Up to Day 31
Part B:Plasma Tmax of AHB-171
Time frame: Up to Day 31
Part B Plasma AUC of AHB-171
Time frame: Up to Day 31
Part B Plasma t1/2 of AHB-171
Time frame: Up to Day 31
Part B: Proportion of CHB who achieved hepatitis B surface antigen (HBsAg) clearance
Time frame: Up to 48 weeks
Part B: HBsAg Decline in CHB Participants at each assessment time point
Time frame: Up to 48 weeks
Part B:Proportion of participants with HBsAg < 1 IU/mL, < 10 IU/mL, and < 100 IU/mL at each assessment time point.
Time frame: Up to 48 weeks
Part B Proportion of participants achieve seroconversion to anti-HBs (HBsAb >10 IU/L) after HBsAg loss.
Time frame: Up to 48 weeks
Part B Proportion of participants with HBV DNA < LLOQ (10 IU/mL)
Time frame: Up to 48 weeks
Part B Proportion of participants with HBsAg < LOD and HBV DNA < LLOQ at each assessment time point
Time frame: Up to 48 weeks
Part B Serum levels of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb , HBeAb , HBeAg
Time frame: Up to 48 weeks
Part B The level of ALT.
Time frame: Up to 48 weeks
PartB: Proportion of participants achieving ALT normalization and time to ALT normalization among those with baseline ALT > ULN.
Time frame: Up to 48 weeks
Part B Correlation between pharmacokinetic and pharmacodynamic parameters of AHB-171
Time frame: Up to 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 20 months is above that.
Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AHB-171